TR200501110T2 - 5-HT2C agonistleri olarak piroloindoller, piridoindoller ve azepinoindoller. - Google Patents

5-HT2C agonistleri olarak piroloindoller, piridoindoller ve azepinoindoller.

Info

Publication number
TR200501110T2
TR200501110T2 TR2005/01110T TR200501110T TR200501110T2 TR 200501110 T2 TR200501110 T2 TR 200501110T2 TR 2005/01110 T TR2005/01110 T TR 2005/01110T TR 200501110 T TR200501110 T TR 200501110T TR 200501110 T2 TR200501110 T2 TR 200501110T2
Authority
TR
Turkey
Prior art keywords
alkyl
treatment
hydrogen
nervous system
central nervous
Prior art date
Application number
TR2005/01110T
Other languages
English (en)
Inventor
Reginald Adams David
Mark Bentley Jonathan
Richard Anthony Roffey Jonathan
John Hamlyn Richard
Gaur Suneel
Alexander James Duncton Matthew
Edward Paul Davidson James
John Bickerdike Michael
Anthony Cliffe Ian
Langham Mansell Howard
Original Assignee
Vernalis Research Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vernalis Research Limited filed Critical Vernalis Research Limited
Publication of TR200501110T2 publication Critical patent/TR200501110T2/tr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Formül (I)'i haiz bir kimyasal bilesik ve farmasötik olarak kabul edilebilir tuzlari ve önilaçlari: n 1,2 veya 3'tür; R1 ve R2 hidrojen ve alkil arasindan seçilir; R3 alkildir; R4 ila R7 hidrojen, halojen, hidroksi, alkil, aril, alkoksi, ariloksi, alkiltio, ariltio, alkilsülfoksil,alkilsülfonil, arilsülfoksil, arilsülfonil, amino, monoalkilamino, dialkilamino, nitro, siyano, karboksaldehit, alkilkarbonil, arilkarbonil, aminokarbonil, monoalkilaminokarbonil, dialkilaminokarbonil, alkoksikarbonilamino, aminokarboniloksi, monoalkilaminokarboniloksi, dialkilaminokarboniloksi, monoalkilaminokarbonilamino ve dialkilaminokarbonilamino arasindan seçilir veya R5 ve R6 birlikte karbosiklik veya heterosiklik bir halka olusturur. Ayrica bilesiklerin tedavide, özellikle merkezi sinir sistemi bozukluklarinin; merkezi sinir sistemi harabiyetinin; kalp-damar hastaliklarinin; mide bagirsak bozukluklari, sekerli diyabet ve uyku apnesinin tedavisinde ve özellikle obesite tedavisinde (DEVAMI VAR).
TR2005/01110T 1998-09-01 1999-09-01 5-HT2C agonistleri olarak piroloindoller, piridoindoller ve azepinoindoller. TR200501110T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9819035.8A GB9819035D0 (en) 1998-09-01 1998-09-01 Chemical compounds VII

Publications (1)

Publication Number Publication Date
TR200501110T2 true TR200501110T2 (tr) 2005-07-21

Family

ID=10838167

Family Applications (2)

Application Number Title Priority Date Filing Date
TR2001/00659T TR200100659T2 (tr) 1998-09-01 1999-09-01 5-HT2C agonistleri olarak piroloindoller, piridoindoller ve azepinoindoller.
TR2005/01110T TR200501110T2 (tr) 1998-09-01 1999-09-01 5-HT2C agonistleri olarak piroloindoller, piridoindoller ve azepinoindoller.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TR2001/00659T TR200100659T2 (tr) 1998-09-01 1999-09-01 5-HT2C agonistleri olarak piroloindoller, piridoindoller ve azepinoindoller.

Country Status (30)

Country Link
US (1) US6433175B1 (tr)
EP (1) EP1109813B1 (tr)
JP (1) JP2002523508A (tr)
KR (2) KR20070062609A (tr)
CN (1) CN1165537C (tr)
AT (1) ATE273308T1 (tr)
AU (1) AU758084B2 (tr)
BR (1) BR9913477A (tr)
CA (1) CA2341991C (tr)
CZ (1) CZ296275B6 (tr)
DE (1) DE69919364T2 (tr)
DK (1) DK1109813T3 (tr)
ES (1) ES2226430T3 (tr)
GB (1) GB9819035D0 (tr)
HK (1) HK1034967A1 (tr)
HR (1) HRP20010126B1 (tr)
HU (1) HUP0103333A3 (tr)
ID (1) ID28842A (tr)
IL (2) IL141659A0 (tr)
MX (1) MXPA01002101A (tr)
NO (1) NO321527B1 (tr)
NZ (1) NZ510097A (tr)
PL (1) PL346427A1 (tr)
PT (1) PT1109813E (tr)
RU (1) RU2232162C2 (tr)
SI (1) SI1109813T1 (tr)
TR (2) TR200100659T2 (tr)
WO (1) WO2000012510A1 (tr)
YU (1) YU16001A (tr)
ZA (1) ZA200101457B (tr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960579B1 (en) 1998-05-19 2005-11-01 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
GB9902047D0 (en) * 1999-01-29 1999-03-17 Cerebrus Ltd Chemical compounds XI
US6465467B1 (en) 1999-05-21 2002-10-15 Biovitrum Ab Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases
GB9918965D0 (en) * 1999-08-11 1999-10-13 Cerebrus Ltd Chemical compounds xxi
SE0002754D0 (sv) * 2000-07-21 2000-07-21 Pharmacia & Upjohn Ab New pharmaceutical combination formulation and method of treatment with the combination
US6818639B2 (en) 2000-07-21 2004-11-16 Biovitrum Ab Pharmaceutical combination formulation and method of treatment with the combination
SE0004245D0 (sv) 2000-11-20 2000-11-20 Pharmacia Ab Novel compounds and their use
JP4204315B2 (ja) 2000-11-20 2009-01-07 ビオヴィトルム・アクチボラゲット(プブリクト) セロトニン5−ht2レセプターのアンタゴニストとしてのピペラジニルピラジン化合物
US6780862B2 (en) 2000-12-20 2004-08-24 Bristol-Myers Squibb Pharma Company Aryl and aminoaryl substituted serotonin receptor agonist and antagonist ligands
KR100539143B1 (ko) * 2000-12-27 2005-12-26 에프. 호프만-라 로슈 아게 인돌 유도체 및 그의 5-ht2b 및 5-ht2c 수용체리간드로서의 용도
WO2002098400A1 (en) 2001-06-01 2002-12-12 Alcon, Inc. Novel arylaminopropane analogues and their use for the treatment of glaucoma
RU2273641C2 (ru) 2001-06-01 2006-04-10 Алькон, Инк. Пираноиндазолы, фармацевтическая композиция на их основе и их использование при лечении глаукомы
EP1392658A4 (en) 2001-06-01 2004-10-13 Alcon Inc NOVEL FUSED INDAZOLES AND INDOLES AND THEIR USE IN THE TREATMENT OF GLAUCOMES
TW593302B (en) 2001-12-20 2004-06-21 Alcon Inc Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma
CA2485537A1 (en) 2002-06-19 2003-12-31 Biovitrum Ab Novel compounds, their use and preparation
JP2006501245A (ja) * 2002-08-30 2006-01-12 アルコン,インコーポレイテッド 置換された5−クロマン−5−イル−エチルアミン化合物および緑内障の治療のためのその使用
BR0316775A (pt) 2002-12-13 2005-11-01 Alcon Inc Novos análogos de benzopirano e seu uso para o tratamento de glaucoma
CL2004000826A1 (es) 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
GB0314967D0 (en) * 2003-06-26 2003-07-30 Hoffmann La Roche Piperazine derivatives
US7435837B2 (en) * 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
WO2005053688A1 (en) 2003-11-26 2005-06-16 Alcon, Inc. Substituted furo[2,3-g] indazoles for the treatment of glaucoma
US7129257B1 (en) 2003-12-15 2006-10-31 Alcon, Inc. Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
US6989445B2 (en) 2003-12-15 2006-01-24 Alcon, Inc. Substituted [1,4]oxazino[2,3-g]indazoles for the treatment of glaucoma
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
WO2006022420A1 (ja) 2004-08-25 2006-03-02 Takeda Pharmaceutical Company Limited 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
EP1807427A2 (en) 2004-11-01 2007-07-18 Wyeth Substituted indolizines and derivatives as cns agents
US7425572B2 (en) 2004-12-08 2008-09-16 Alcon, Inc. Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma
AU2006228378A1 (en) 2005-03-31 2006-10-05 Pfizer Products Inc. Cyclopentapyridine and tetrahydroquinoline derivatives
PE20061319A1 (es) * 2005-04-22 2006-12-28 Wyeth Corp Cristales formados de clorhidrato de {[(2r)-7-(2,6-diclorofenil)-5-fluoro-2-3-dihidro-1-benzofurano-2-il]metil}amina
ATE514698T1 (de) * 2005-05-03 2011-07-15 Hoffmann La Roche Tetracyclische azapyrazinoindoline als 5-ht2- liganden
EP2742936A1 (en) 2006-05-16 2014-06-18 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
EP2044029B1 (en) * 2006-07-14 2011-01-26 Pfizer Products Inc. Tartrate salt of (7s)-7-[(5-fluoro-2-methyl-benzyl)oxy]-2-[(2r)-2-methylpiperazin-1-yl]-6,7-dihydro-5h-cyclopenta[b]pyridine
US20100266504A1 (en) 2007-11-15 2010-10-21 Takahiro Matsumoto Condensed pyridine derivative and use thereof
KR101062376B1 (ko) 2008-04-10 2011-09-06 한국화학연구원 신규 인돌 카르복실산 비스피리딜 카르복사마이드 유도체,이의 제조방법 및 이를 유효성분으로 함유하는 조성물
WO2011071136A1 (ja) 2009-12-11 2011-06-16 アステラス製薬株式会社 線維筋痛症治療剤
US20130267500A1 (en) 2010-09-01 2013-10-10 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
CN102964352B (zh) * 2012-11-23 2015-04-08 华中师范大学 具有生物活性的手性2,3-二氢吡咯[1,2-a]吲哚衍生物及其不对称合成方法
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
US20210052600A1 (en) 2017-12-27 2021-02-25 Takeda Pharmaceutical Company Limited Therapeutic agents for stress urinary incontinence and incotinence of feces
US11485734B2 (en) 2018-10-02 2022-11-01 Northwestern University Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2C (5-HT2C)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3250783A (en) * 1964-09-21 1966-05-10 American Cyanamid Co Novel pyrrolo (1, 2-alpha) indoles
US4134894A (en) * 1978-05-04 1979-01-16 Warner-Lambert Company Pyrrolo[1,2-a]indole compounds
GB8416724D0 (en) * 1984-06-30 1984-08-01 Sorbio Sa Lab Active compounds
US4778812A (en) * 1987-06-12 1988-10-18 American Home Products Corporation 2,3-dihydro-9-methyl-1H-pyrrolo[1,2-a]indol-1-amines and derivatives thereof
GB8802127D0 (en) * 1988-02-01 1988-03-02 Glaxo Group Ltd Chemical compounds
JP2831467B2 (ja) * 1992-03-12 1998-12-02 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 5ht▲下4▼−受容体アンタゴニストとしての縮合インドール誘導体
EP0572863A1 (de) * 1992-06-05 1993-12-08 F. Hoffmann-La Roche Ag ZNS Pyrazinoindole
HUT68293A (en) * 1993-03-08 1995-06-28 Fujisawa Pharmaceutical Co 5-ht antagonists as acting agent against cerebrovascular deseases
US5629427A (en) * 1993-08-26 1997-05-13 Peterson; Dwight M. 2,7-diaminomitosene analogues

Also Published As

Publication number Publication date
ES2226430T3 (es) 2005-03-16
BR9913477A (pt) 2001-10-09
ATE273308T1 (de) 2004-08-15
WO2000012510A1 (en) 2000-03-09
ID28842A (id) 2001-07-05
IL141659A0 (en) 2002-03-10
AU758084B2 (en) 2003-03-13
EP1109813B1 (en) 2004-08-11
GB9819035D0 (en) 1998-10-28
ZA200101457B (en) 2002-02-21
DK1109813T3 (da) 2004-12-20
CA2341991A1 (en) 2000-03-09
IL141659A (en) 2007-10-31
KR20010079715A (ko) 2001-08-22
HRP20010126B1 (en) 2005-06-30
CN1165537C (zh) 2004-09-08
US6433175B1 (en) 2002-08-13
NO20010991D0 (no) 2001-02-27
HUP0103333A2 (hu) 2002-01-28
HUP0103333A3 (en) 2002-07-29
DE69919364D1 (de) 2004-09-16
NZ510097A (en) 2003-06-30
PT1109813E (pt) 2004-11-30
PL346427A1 (en) 2002-02-11
CN1325399A (zh) 2001-12-05
KR100768595B1 (ko) 2007-10-18
DE69919364T2 (de) 2005-08-04
NO20010991L (no) 2001-04-23
CZ2001772A3 (cs) 2001-07-11
JP2002523508A (ja) 2002-07-30
KR20070062609A (ko) 2007-06-15
HRP20010126A2 (en) 2002-02-28
CA2341991C (en) 2009-04-07
TR200100659T2 (tr) 2001-10-22
HK1034967A1 (en) 2001-11-09
CZ296275B6 (cs) 2006-02-15
MXPA01002101A (es) 2002-08-20
YU16001A (sh) 2003-10-31
AU5637599A (en) 2000-03-21
NO321527B1 (no) 2006-05-15
RU2232162C2 (ru) 2004-07-10
SI1109813T1 (en) 2005-02-28
EP1109813A1 (en) 2001-06-27

Similar Documents

Publication Publication Date Title
TR200501110T2 (tr) 5-HT2C agonistleri olarak piroloindoller, piridoindoller ve azepinoindoller.
ATE282613T1 (de) Pyrrolochinoline zur behandlung von fettleibigkeit
DE69930397D1 (de) Indazolderivate mit 5-ht2-rezeptor-aktivität
PT1147110E (pt) Derivados de pirazino (aza)-indol
MXPA03011981A (es) 3-fluoruro-pirrolidinas como agentes antidiabeticos.
YU69902A (sh) Novi derivati piperazina
NO953305L (no) Antranilsyrederivat
DE60032482D1 (de) 5-cyano-2-aminopyrimidine derivate
UA66825C2 (uk) Азаполіциклічні сполуки, конденсовані з арилом, фармацевтична композиція, спосіб лікування та спосіб зниження нікотинової залежності
AR029815A1 (es) Derivados aza-indolicos, un proceso para su preparacion, composicion farmaceutica, un metodo para su elaboracion y el uso de dichos derivados para la manufactura de un medicamento
WO2000017170A3 (en) N1-substituted benzopyrazoles as inhibitors of 5-ht2 receptors
NZ527249A (en) Purine derivatives as purinergic receptor antagonists
MY108909A (en) Indole derivatives
ES2143487T3 (es) 1,2,4-oxadiazolil-fenoxialquilisoxazoles y su empleo como agentes antivirales.
WO2000012482A3 (en) Indazole derivatives with 5-ht2 receptor activity
MXPA04003278A (es) Derivados de 5-metoxi-8-aril-?1,2,4?triazolo?1,5-a?piridina como antagonistas del receptor de adenosina.
NZ337749A (en) Benzimidazole derivative and their use in allergy-related disease